Quick Facts

• Relief Domain: Major depressive disorder
• Primary Indications: Obsessive-compulsive disorder (OCD), panic disorder
• Additional Uses: Post-traumatic stress disorder (PTSD), social anxiety disorder

Sertex is a prescription medication indicated for the management of specific mental health conditions. Its main therapeutic uses include addressing major depressive disorder in adults, assisting in the control of obsessive-compulsive disorder (OCD) for both adults and pediatric patients (aged 6–17 years), and treating panic disorder. The medication is also utilized to manage symptoms associated with post-traumatic stress disorder (PTSD) and social anxiety disorder.

Treatment benefits center on helping to reduce the frequency and severity of symptoms in these conditions. For instance, in depression, it aims to improve mood, sleep patterns, and energy levels. For anxiety-related conditions like panic disorder and social anxiety, it works to diminish fear, panic attacks, and avoidance behaviors. Continued management with this agent helps to sustain symptom control and prevent the return of symptoms, which supports the patient's capacity for daily functioning and enhances overall well-being.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility and Contraindications for Sertex

Official regulatory guidelines define specific populations that are eligible or ineligible for treatment with Sertex (Sertraline). These criteria are based on factors such as age, concurrent medication use, and existing health conditions.

Absolute Non-Eligibility (Contraindications)

Sertex must not be used by patients with a known hypersensitivity to the drug or those who are currently taking Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid, or the drug Pimozide. Use is also strictly prohibited for patients with unstable epilepsy or those in a manic phase of bipolar disorder.

---

Age-Specific Eligibility

Population	Eligibility Status (Regulatory Label)
Adults (18+ years)	Eligible for all approved indications.
Pediatric Patients (6–17 years)	Eligible only for the treatment of Obsessive-Compulsive Disorder (OCD).
Children under 6 years	Use not established for any indication.

---

Restricted or Conditional Use

Patients with mild hepatic impairment may require a lower or less frequent dose. Caution is advised for those with a history of seizure disorders, bleeding disorders, or when used during the third trimester of pregnancy. While renal impairment generally does not require dose adjustment, caution is advised for all use in patients with compromised organ function.

Sertex Interactions with other medicines and products

Co-administration of Sertex is strictly prohibited with several medicinal products. The combination is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including the antibacterial Linezolid. This prohibition requires a mandatory washout period: at least 14 days must pass after stopping an MAOI before initiating Sertex, and at least 7 days after stopping Sertex before starting an MAOI. Other contraindicated combinations include Pimozide and Thioridazine. The oral concentrate formulation has a unique restriction and is contraindicated with Disulfiram due to its ethanol content.

---

The official interaction profile identifies pharmacodynamic potentiation with other serotonergic agents (e.g., Triptans, St. John's Wort), which is documented to increase the risk of Serotonin Syndrome. Co-use with antiplatelet agents (e.g., NSAIDs) and anticoagulants (e.g., Warfarin) increases the documented risk of hemorrhage.

Sertex is a regulated inhibitor of the CYP2D6 enzyme, a documented pharmacokinetic interaction that may lead to reduced clearance of co-administered CYP2D6 substrates. Additionally, co-administration with potent inhibitors of CYP3A4 can increase Sertex plasma concentrations. When taking the Sertex tablet, co-administration with food is documented to increase the peak plasma concentration (Cmax). For populations with hepatic impairment, a significant increase in Sertex exposure is officially noted due to altered clearance.

Selective Serotonin Reuptake Inhibition

Sertex primarily acts as a Selective Serotonin Reuptake Inhibitor (SSRI) by binding to the Serotonin Transporter (SERT) protein on the presynaptic neuronal membrane. This interaction blocks the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the neuron. The resulting immediate consequence is an increase in the extracellular concentration and duration of serotonin availability, which modulates the activity of key serotonergic signaling pathways.

---

Chronic Neuroplastic and Dual Modulation

With chronic exposure, the sustained increase in synaptic serotonin drives adaptive changes, including the desensitization and downregulation of presynaptic inhibitory autoreceptors. This systemic adjustment influences the activity of neural processes and promotes the enhanced expression of neurotrophic factors like BDNF. Additionally, Sertex exhibits a secondary mechanism by functioning as an antagonist at the intracellular Sigma-1 (sigma1) receptor. This dual action influences neuronal excitability and cellular stress responses, contributing to the chronic modulation of affective and stress response systems that shapes the overall pharmacodynamic effect profile.

How to Use Sertex

Sertex is provided as a film-coated tablet intended for oral administration.

Administration Scope	Detail
Route of Administration	Oral
Dosing Schedule (Adults)	Initial dose is 10 mg once daily. The dose may be increased to a maximum of 20 mg once daily after at least 7 days.
Timing in Relation to Meals	May be taken with or without food.
Preparation Requirements	Swallow the tablet whole. Do not crush, chew, or split the tablet.

---

Population-Specific and Procedural Rules

Age-Group Administration: For geriatric patients (aged 65 years and older), the recommended starting dose is 5 mg once daily. Dose adjustments must be made cautiously.

Missed-Dose Rules: If a scheduled dose is missed, take the dose as soon as possible, unless it is close to the time of the next scheduled dose. If so, skip the missed dose and resume the regular dosing schedule. Do not take two doses at the same time to compensate for a missed dose.

Discontinuation Protocol: When discontinuing treatment, the dose should be gradually reduced over a period of at least two weeks. This structured reduction is necessary to complete the course of therapy.

---

The administration of this medication involves a required daily frequency of once daily and the method of swallowing the tablet whole.

Research Evidence / Overview of Studies for Sertex

Evidence for Use in Major Depressive Disorder (MDD)

Research on Sertex in adults with Major Depressive Disorder (MDD) primarily involves numerous short-term (typically 6- to 12-week) Randomized Controlled Trials (RCTs). These studies examined the outcomes of individuals receiving Sertex against those receiving an inactive substance (placebo). Outcomes were measured using tools that track changes in depressive symptom severity and the rate at which symptoms significantly lessened or disappeared (remission). Long-term studies were also conducted to explore the patterns of symptom return (relapse) after an initial observed change. Research describes changes measured during the study period on these standardized scales, contributing to the broader evidence landscape. Despite the large volume of research, certain aspects remain uncertain, particularly regarding long-term functional recovery beyond immediate symptom management.

---

Evidence for Use in Obsessive-Compulsive Disorder (OCD) and Panic Disorder

Sertex was studied for its use in both Obsessive-Compulsive Disorder (OCD) and Panic Disorder through multiple placebo-controlled RCTs. For OCD, studies examined measurements related to changes in symptom severity using specialized scales, including in pediatric patients. For Panic Disorder, research evaluated measurements related to the frequency and intensity of panic attacks over defined time intervals. The evidence contributes to understanding symptom patterns in these conditions. Key research limitations include the observation that reported changes in OCD symptoms may be different in magnitude than those observed in depression trials. Data for certain complicated cases of Panic Disorder remain insufficient.

---

Evidence for Use in Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder

The research for Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder relies on RCTs. For PTSD, research evaluated outcomes reflecting daily functioning and monitored measurements in the core symptom groups. For Social Anxiety Disorder, studies explored symptom intensity and variability. Findings were mixed across the total study landscape; some research involving certain veteran groups was observed in some studies to be less distinct from placebo. Evidence for both conditions is often considered to have moderate certainty because findings were mixed or the available long-term data for certain subgroups are limited. The long-term effects are not fully established.

---

What is Still Uncertain About Sertex Research

The evidence landscape highlights areas where additional research is needed. A consistent limitation across various indications is that long-term effects are not fully established, particularly following the cessation of treatment. Furthermore, data for certain groups remain insufficient, including patients with treatment-resistant conditions. Comparative evidence against some newer pharmacological and non-pharmacological interventions is lacking in specific conditions. The research highlights what is known — and what is still uncertain.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE): Depression in adults: treatment and management (NG222)

Common questions about Sertex (FAQ)

---

Q: What is Sertex used for?

According to official product information, Sertex is indicated to treat Major Depressive Disorder (MDD). It is also approved for the treatment of Obsessive-Compulsive Disorder (OCD) in adults and children.

---

Q: How does Sertex work in the body?

Regulatory documents state that Sertex belongs to a class of medicines called Selective Serotonin Reuptake Inhibitors (SSRIs). Sertex works by increasing the levels of a natural substance in the brain called serotonin. This action helps to improve mood and reduce symptoms related to depression and OCD.

---

Q: Is Sertex a controlled substance?

Official product information specifies that Sertex is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is generally not considered to have a high potential for abuse or dependence compared to scheduled medicines.

---

Q: Can children take Sertex?

Studies and official information indicate that Sertex is approved for the treatment of Obsessive-Compulsive Disorder (OCD) in children. However, its use for Major Depressive Disorder in pediatric patients may be limited, and specific eligibility criteria apply.

---

Q: Does Sertex cause weight gain?

The regulatory documents state that changes in weight, including both weight gain and weight loss, have been reported in clinical studies of Sertex. This is listed among the possible effects reported in clinical studies.

---

Q: What should I do if I miss a dose of Sertex?

Official product labeling provides specific instructions for managing missed doses. Regulatory information generally advises taking a missed dose when remembered unless the next dose is due soon. It is also explicitly advised against taking a double dose to compensate for a missed one.

---

Q: How long does Sertex take to start working?

According to official product information, it may take several weeks before the full therapeutic benefit of Sertex is felt. While initial improvements in areas like sleep or energy may be seen within the first 1–2 weeks, full mood changes can take up to 4–6 weeks.

---

Q: Can I drink alcohol while taking Sertex?

The official product information strongly advises that alcohol consumption should be avoided while taking Sertex. Combining alcohol and Sertex may increase the risk of certain side effects and can impair judgment and motor skills, according to regulatory warnings.

---

Q: Is Sertex safe to take during pregnancy or while breastfeeding?

Regulatory documents indicate that use during pregnancy or while breastfeeding requires careful evaluation by a healthcare provider. Official information suggests its use should only occur if the potential benefit justifies the potential risk to the fetus or infant, as the drug is known to pass into breast milk.

---

How to Store and Dispose of Sertex (Sertraline Hydrochloride)

Sertex must be stored according to official regulatory labeling to ensure its stability. The medication requires storage at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with protection from light and excessive moisture. The container must be kept tightly closed.

For the oral concentrate solution, storage below 15 C is prohibited, and the solution must be used within 28 days of first opening. When handling the concentrate, contact with skin should be avoided. All forms of Sertex must be kept out of the sight and reach of children.

Unused or expired Sertex must be discarded in compliance with local regulations. Regulatory guidance specifies that the medicine must not be disposed of via household waste or wastewater.